Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Observational Study, to Evaluate the Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for Autologous Stem Cell Transplantation (ASCT): Alcyone-optimized Real World Evidence (RWE) Data

NCT05218603 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT05218603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05218603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Observational Study, to Evaluate the Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for Autologous Stem Cell Transplantation (ASCT): Alcyone-optimized Real World Evidence (RWE) Data
Lead sponsor
PETHEMA Foundation
Phase
Observational
Overall status
Unknown status
Start date
November 30, 2021
Completion date
November 6, 2025
Enrollment
100 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, non-eligible for autologous stem cell transplantation (asct)